Corvus Pharmaceuticals (CRVS) Operating Income (2015 - 2026)

Corvus Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$14.9 million for Q1 2026.

• In Q1 2026, Operating Income fell 49.94% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$47.9 million (down 53.53% YoY), while the FY2025 annual figure was -$43.0 million, down 55.99% from the prior year.
• Operating Income was -$14.9 million for Q1 2026 at Corvus Pharmaceuticals, down from -$12.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$5.6 million in Q3 2023 to a low of -$14.9 million in Q1 2026.
• Historically, Operating Income has averaged -$8.3 million across 5 years, with a median of -$7.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Operating Income soared 55.42% in 2023, then sank 72.87% in 2025.
• A 5-year view of Operating Income shows it stood at -$5.7 million in 2022, then grew by 0.26% to -$5.7 million in 2023, then sank by 43.43% to -$8.1 million in 2024, then slumped by 50.73% to -$12.2 million in 2025, then declined by 21.77% to -$14.9 million in 2026.
• The last three Operating Income figures came in at -$14.9 million (Q1 2026), -$12.2 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.